- Conditions
- Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 91
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 865–888
of 908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- bevacizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania
- Conditions
- Age Related Macular Degeneration
- Interventions
- Longvida curcumin, placebo
- Drug · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Age Related Macular Degeneration (ARMD)
- Interventions
- Elamipretide, Placebo
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Huntington Beach, California + 28 more
- Conditions
- Diabetic Retinopathy, Macular Edema
- Interventions
- MK-8748, Aflibercept
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Winter Haven, Florida • Hagerstown, Maryland • Winston-Salem, North Carolina + 4 more
- Conditions
- Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
- Interventions
- ACDN-01
- Drug
- Lead sponsor
- Ascidian Therapeutics, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 11
- States / cities
- San Francisco, California • Gainesville, Florida • Miami, Florida + 8 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- OTX-TKI/Sham, Aflibercept/Sham
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Bakersfield, California • Oxnard, California • Altamonte Springs, Florida + 3 more
- Conditions
- Hippel-Lindau Disease
- Interventions
- EYE001
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Iptacopan (LNP023), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 22
- States / cities
- Fullerton, California • Huntington Beach, California • Rancho Cordova, California + 19 more
- Conditions
- Macular Degeneration
- Interventions
- Bevasiranib
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Artesia, California + 19 more
- Conditions
- Glaucoma, Macular Disease, Keratoconus
- Interventions
- OCT imaging, the FDA Cleared iVue
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Nidek MP-3
- Device
- Lead sponsor
- Doheny Image Reading Center
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Drug: GB-102, Aflibercept
- Drug
- Lead sponsor
- Graybug Vision
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 33
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 28 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- carbidopa-levodopa 25-100 mg tablets
- Drug
- Lead sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
- Individual
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
- Interventions
- Injection
- Biological
- Lead sponsor
- Cellio Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Palo Alto, California • Sacramento, California
- Conditions
- Maculopathy, Age-Related
- Interventions
- Anecortave Acetate 15 mg, Triamcinolone Acetate 4 mg, Photodynamic Therapy with Verteporfin, Thermal Laser
- Drug · Procedure
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age-related Macular Degeneration
- Interventions
- Atorvastatin 80mg
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Pathologic Neovascularization, Retinal Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetic Macular Edema
- Interventions
- OXU-001, Semi-automated suprachoroidal illuminated microcatheter, Ozurdex® Ophthalmic Intravitreal Implant
- Drug · Device
- Lead sponsor
- Oxular Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Clearwater, Florida • Oak Forest, Illinois + 5 more
- Conditions
- Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease, Vitreoretinal Abnormality, Intraretinal Hyporeflective Space, Subretinal Hyporeflective Space, IS/OS (Ellipsoid Zone) Disruption, Retinal Pigment Epithelium (RPE) Elevation, Retinal Pigment Epithelium (RPE) Atrophy
- Interventions
- PathFinder 1.0 on CIRRUS HD-OCT
- Device
- Lead sponsor
- Carl Zeiss Meditec-Dublin CoCe
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Mountain View, California • San Francisco, California + 3 more
- Conditions
- Age-Related Macular Degeneration, Cataract
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Foresee Home
- Device
- Lead sponsor
- Notal Vision Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Toms River, New Jersey
- Conditions
- Radiation Retinopathy, Macular Edema
- Interventions
- Aflibercept every 2 months, Aflibercept monthly
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Houston, Texas